Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate

Archives of Internal Medicine

Volumn 159, Issue 21, 1999, Pages 2542-2550

  Strand, Vibeke ^a   Cohen, Stanley ^b   Schiff, Michael ^c   Weaver, Arthur ^d   Fleischmann, Roy ^b   Cannon, Grant ^e   Fox, Robert ^f   Moreland, Larry ^g   Olsen, Nancy ^h   Furst, Dan ⁱ   Caldwell, Jacques ^j   Kaine, Jeffrey ^k   Sharp, John ^l   Hurley, Frank ^m   Loew Friedrich, Iris ⁿ  

^a STANFORD UNIVERSITY   (United States)

^b METROPLEX CLINICAL RESEARCH CENTER   (United States)

^c Denver Arthritis Clinic PC   (United States)

^d Arthritis Center of Nebraska   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f SCRIPPS CLINIC   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ Virginia Mason Health System   (United States)

^j Halifax Research Center   (United States)

^k Sarasota Arthritis Center   (United States)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m IQVIA   (United States)

ⁿ SANOFI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; LEFLUNOMIDE; METHOTREXATE; PLACEBO;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; TRANSAMINASES; TREATMENT OUTCOME;

EID: 0033596065     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.21.2542     Document Type: Article

References (31)

1. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med. 1985;103:489-496.
2. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989;16:313-320.
3. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818-822.
4. Williams HJ, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1985;38:721-730.
5. Choy EHS, Scott DL. Drug treatment of rheumatic diseases in the 1990s: achievements and future developments. Drugs. 1997;53:337-348.
6. Silva HT, Morris RE. Leflunomide and the malanonitriloamides. Am J Med Sci. 1997;313:289-301.
7. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996;35:1270-1273.
8. Herrmann M, Grangou CG, Kirschbaum B. Cell cycle control of the de novo pyrimidlne synthesis inhibitor leflunomidelunomide through the p53 and p21 pathways [abstract]. Arthritis Rheum. 1997;40:S177.
9. Silva HT, Cao W, Shorhouse R, Morris RE. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant Proc. 1996;28:3082-3084.
10. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 1995;38:1595-1603.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
12. Pincus T, Summey JA, Sorraci SA, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346-1353.
13. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789-793.
14. Bombardier C, Buchbinder R, Tugwell P. Efficacy of cyclosporin A in rheumatoid arthritis: long-term follow-up data and the effect on quality of life. Scand J Rheumatol Suppl. 1992;95:29-33.
15. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30:473-483.
16. Bluhm GB, Sharp JT, Tilley BC, et al. Radiographic results from the minocycline in rheumatoid arthritis (MIRA) trial. J Rheumatol. 1997;24:1295-1302.
17. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis clinical trials. Arthritis Rheum. 1995;38:725-735.
18. Kremer JM, Alarcon GA, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis, suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994; 37:316-328.
19. Food and Drug Administration. Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). Final guidance issued February 1999. Available at: http:// www.fda.gov/cder/guidance/1208dft.pdf. Accessed August 18, 1999.
20. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-147.
21. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med. 1999;130:478-486.
22. McKay J, Rau R, Weisman M, for the Lenercept 362 Study Group. A double-blind, randomized, 6 arm, parallel-group, dose finding, double dummy, multicenter comparison of sTNFr55-IgG (Ro45-2081-lenercept) subcutaneous to reference treatment with oral methotrexate (MRX) and their combination in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. 1998;41:S132.
23. Goldsmith C, Boers M, Bombardier C, Tugwell P, for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles. J Rheumatol. 1993; 20:561-565.
24. Wells G, Tugwell P, Kraag G, Baker P, Groh J, Redelmeier D. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993;20:557-560.
25. Guzman J, Maetzel A, Peloso P, Yeung M, Bombardier C. Disability scores in DMARD trials: what is a clinically important change? Arthritis Rheum. 1996;39: S208.
26. Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as 50% or 70% improvement in core set measures, rather than 20%? Arthritis Rheum. 1998;41:1564-1570.
27. Cohen S, Rutstein J, Luggen M, et al. Comparison of the safety and efficacy of cyclosporine A and methotrexate in refractory rheumatoid arthritis. Arthritis Rheum. 1993;36:S56.
28. Neoral. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Co Inc; 1998:1182-1184.
29. Ortiz A, Shea B, Suarez-Almazor M, Moher D, Wells G, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a meta-analysis of randomized controlled trials. J Rheumatol. 1997;25:36-42.
30. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol. 1998;25:408-416.
31. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999;42:1322-1328.